Feed VCEL
VC

Vericel

VCEL · NASDAQ

$40.02 +1.19% (+$0.47)
1M -5.39%
Market Cap $2.05B
P/E Ratio 84.61x
Div. Yield -
ROE 6.91%

Bulios Fair Price

$21.16

47.1% downside

Trenutna cena

$40.02

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica VCEL trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
16 /100
Expensive
P/FCF 41.28x
P/E 84.61x
P/B 5.54x
Growth
100 /100
Growing
Book val. growth 22.64%
Rev. growth 18.90%
FCF growth 34.86%
Profitability
66 /100
Moderate
Op. margin 5.95%
Gross margin 74.56%
FCF margin 16.21%
Quality
31 /100
Poor
ROA 4.82%
ROIC 3.79%
Asset turnover 0.61x
Debt
100 /100
Low
Int. coverage 40.17x
Debt/Equity 0.25x
Net debt/EBITDA -0.85x
Stability
56 /100
Moderate
EPS volatility 189.95%
Beta 1.05x
Profitable years 2

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o VCEL
Online

O podjetju

Vericel Corporation is a biotechnology company that specializes in the development and commercialization of advanced therapies for tissue regeneration. The company primarily focuses on treating severe wounds, burns, and orthopedic conditions, offering autologous cell therapies that use a patient’s own cells to support healing and regeneration. Its key products include Epicel, a therapy for burn treatment, and Carticel, a cell therapy for cartilage repair.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Dominick C. Colangelo

Employees

398

Headquarters

Burlington

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

45d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.